Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…

Read More

Ning Wang talks about “Single cell sequencing: a powerful approach to profile tumor microenvironment” at Advance Genetic Sequencing Virtual Conference 2021

Ning Wang talks about “Single cell sequencing: a powerful approach to profile tumor microenvironment” at Advance Genetic Sequencing Virtual Conference 2021

Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA. Marketsandmarkets took this opportunity to pick his brains on the newfound developments…

Read More

Grace Zhao, Co-founder, Avida Biomed discusses- “Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting”

Grace Zhao, Co-founder, Avida Biomed discusses- “Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting”

Grace Zhao is a co-founder of Avida Biomed, a biotech start-up specializing in genomic technology innovation for molecular diagnostics. At Avida, Grace co-invented Point-n-Seq, a new platform technology to advance liquid biopsy for early detection of cancer and other diseases. Utilizing the ultra-efficient, hybridization-based pre-amplification enrichment of target molecules from nanogram level cell free DNA (cfDNA), Point-n-Seq enables the first targeted mutation and methylation cfDNA dual analysis solution on market. Grace is currently the head of clinical research defining and executing company-wide clinical research strategy. Before Avida, Grace co-founded AccuraGen,…

Read More

Multiple factors & challenges preventing cell and gene therapies to be widely used- 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference

Multiple factors & challenges preventing cell and gene therapies to be widely used- 3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference

3rd Annual MarketsandMarkets Cell & Gene Therapy Manufacturing Virtual Conference to be held on 28th – 29th October 2021 will host industry giants like Advanced Cell & Gene Therapy LLC, Cell & Gene Therapy Consulting LLC, panCella, Sigilon Inc, Biotechnology Biopharmaceuticals and many more. The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7 billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of…

Read More

Discussing Top 10 Disruptions in BioPharma Manufacturing at the MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT!

Discussing Top 10 Disruptions in BioPharma Manufacturing at the MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT!

February 26th – MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT on the March 11, 2021 will hostindustry giants Fresenius Kabi, Charles River Laboratories, GenScript ProBio, Pall Corporation and MilliporeSigma to present their thoughts on the Top 10 Disruptions Through BioPharma Manufacturing in the next 5 year! MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT will gather 100+ professionals from industry giants such as Biocon Biologics, Ology Bioservices, Celonic AG, Gyroscope Therapeutics, GenIbet, Hemobras, H2i Group, MilliporeSigma, Orange Grove Bio, HORIBA, Porex Life Sciences Institute, Kaneka, Lonza, Cytiva, GEA North America, Batavia Biosciences, Nova…

Read More

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets Epigenetics Congress

Speaker Interview With Gavin Reynolds For 4TH Annual MarketsandMarkets  Epigenetics Congress

London, UK July 29, 2019 – MarketsandMarkets recently interviewed Gavin Reynolds, Professor Emeritus, Queen’s University Belfast, UK regarding the 4th Annual MarketsandMarkets Epigenetics Congress, taking place on 3-4 October 2019 at Radisson Blu Edwardian, Grafton, London, UK. Gavin Reynolds is Honorary Professor at Sheffield Hallam University and Professor Emeritus, previously Chair of Neuroscience, at Queen’s University Belfast. His main research interests lie in two directions: the neurotransmitter pathology of schizophrenia, and the mechanisms underlying the beneficial and adverse effects of antipsychotics and other psychoactive drugs, with a recent focus on pharmacogenetic and…

Read More

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

AveXis Directs to Catalent’s Paragon for Extra Gene Therapy Producing Capacity

Catalent has approved AveXis that, a Novartis Company to use its brand-new commercial manufacturing center near Baltimore-Washington International Airport as an extra site production site for its spinal muscular atrophy (SMA) gene therapy Zolgensma® (onasemnogene abeparvovec-xioi). A collaboration contract was signed by Catalent and AveXis to ensure long term strategic agreement but has not been disclosed yet. AveXis will use the dedicated production space within Paragon’s Harmans, MD, facility, a 151,000-square-foot old warehouse that Paragon changed into a contract developing and a manufacturing site which opened in April. Andy Stober,…

Read More